Context.—Although cholesterol-reducing treatment has been shown to reduce fatal and
nonfatal coronary disease in patients with coronary heart disease (CHD), it is unknown
whether benefit from the reduction of low-density lipoprotein cholesterol (LDL-C) in patients
without CHD extends to individuals with average serum cholesterol levels, women, and
older persons. Objective.—To compare lovastatin with placebo for prevention of the first
acute major coronary event in men and women without clinically evident atherosclerotic …